KREBSBIO
Krebs Biochemicals and Industries Limited (KREBSBIO) Stock Analysis
Krebs Biochemicals and Industries Limited manufactures specialty enzymes and biochemicals for pharma and industrial use. Its products include statin intermediates and custom fermentation outputs. The company serves regulated pharmaceutical customers. It is a listed biotech chemicals firm.
Healthcare › Drug Manufacturers - Specialty & Generic
₹60.20
+7.48% 1W | -13.90% 52W
Market Cap
130 CR
P/E Ratio
–
52W High
₹76.8
52W Low
₹38.3
Div. Yield
0%
Beta
0.9
50 DMA
₹57.1
200 DMA
₹58.1
Profit Margin
-55.9%
Inst. Own.
0%
📊 CONSOLIDATION
📊 CONSOLIDATION
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.58 | 14.89 | 12.98 | 11.97 | 12.89 | 12.86 | 11.47 | 6.10 | 5.48 | 4.17 | 7.27 | 6.81 | 6.98 |
| Expenses | 13.20 | 15.79 | 15.07 | 15.09 | 15.08 | 15.58 | 16.18 | 11.51 | 7.57 | 6.97 | 6.97 | 7.67 | 6.16 |
| Operating Profit | -2.62 | -0.90 | -2.09 | -3.12 | -2.19 | -2.72 | -4.71 | -5.41 | -2.09 | -2.80 | 0.30 | -0.86 | 0.82 |
| OPM % | -24.76% | -6.04% | -16.10% | -26.07% | -16.99% | -21.15% | -41.06% | -88.69% | -38.14% | -67.15% | 4.13% | -12.63% | 11.75% |
| Other Income | 0.04 | 0.17 | 0.03 | 0.21 | 0.03 | 0.09 | 0.25 | 0.34 | 0.01 | 0.01 | 0.00 | 2.00 | 0.16 |
| Interest | 1.10 | 1.13 | 1.19 | 1.27 | 1.32 | 1.42 | 1.56 | 1.61 | 1.65 | 1.73 | 1.79 | 1.91 | 1.88 |
| Depreciation | 1.65 | 1.71 | 1.73 | 1.67 | 1.69 | 1.71 | 1.72 | 1.57 | 1.60 | 1.62 | 1.63 | 1.57 | 1.59 |
| Profit before tax | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.25 | -5.33 | -6.14 | -3.12 | -2.34 | -2.49 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.27 | -5.32 | -6.14 | -3.13 | -2.34 | -2.48 |
| EPS in Rs | -2.47 | -1.66 | -2.31 | -2.71 | -2.40 | -2.67 | -3.59 | -3.84 | -2.47 | -2.85 | -1.45 | -1.09 | -1.15 |
| Metric | Mar 20156m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 1 | 3 | 34 | 48 | 33 | 54 | 60 | 52 | 50 | 43 | 24 | 25 |
| Expenses | 5 | 14 | 11 | 41 | 58 | 52 | 71 | 94 | 68 | 59 | 58 | 29 | 28 |
| Operating Profit | -5 | -12 | -8 | -8 | -10 | -19 | -18 | -34 | -16 | -9 | -15 | -5 | -3 |
| OPM % | -1,088% | -248% | -22% | -20% | -56% | -33% | -57% | -30% | -17% | -35% | -23% | -10% | |
| Other Income | 3 | 1 | -0 | -1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 2 |
| Interest | 4 | 1 | 3 | 5 | 6 | 6 | 6 | 5 | 3 | 5 | 6 | 7 | 7 |
| Depreciation | 2 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 7 | 7 | 7 | 6 | 6 |
| Profit before tax | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -17 | -14 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| Net Profit | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -17 | -14 |
| EPS in Rs | -6.82 | -10.33 | -9.67 | -10.73 | -12.03 | -16.04 | -14.45 | -20.65 | -11.45 | -9.15 | -12.50 | -7.85 | -6.54 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | -23.0% | -15.0% | 35.0% |
| Profit CAGR | 10.0% | 7.0% | 0.0% |
Shareholding Pattern
Promoters72.74%
FIIs0.50%
Public26.76%
Promoters72.74%
FIIs0.50%
Public26.76%
Promoters72.74%
FIIs0.50%
Public26.77%
Promoters72.74%
FIIs0.50%
Public26.76%
Promoters72.74%
FIIs0.50%
Public26.75%
Promoters72.74%
FIIs0.50%
Public26.76%
Promoters72.74%
FIIs0.50%
Public26.75%
Promoters72.74%
FIIs0.50%
Public26.75%
Promoters72.74%
FIIs0.50%
Public26.77%
Promoters72.74%
FIIs0.50%
Public26.75%
KREBSBIO
Holdings Analysis
Key strengths & risk signals
51
Overall
35
Fundamental
68
Technical
Risks (3)
Cannot calculate PEG - insufficient growth data.
WEAK YEAR! Stock declined 13.9% in the last year.
BEARISH TREND! 50-day average (57.1) is below 200-day average (58.1) - negative signal.
Strengths (3)
BULLISH SENTIMENT! In last 30 days: 17 up days, 13 down days. Avg volume on up days: 63,338 vs down days: 21,677. Ratio: 2.92x
STRONG MOMENTUM! Price has grown across all timeframes - up 7.5% (1 week), 8.2% (1 month), 12.1% (3 months). Momentum is accelerating.
STRONG POSITION! Current price (60.2) is above both moving averages.
Fundamental & Technical Analysis
51Overall
35Fundamental
68Technical
Fundamental Breakdown
Growth Quality
4/30
Revenue CAGR: -23.1% (DECLINING, 2/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! -55.9% profit margin - thin profits.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 26.77% public ownership - balanced ownership structure.
Stability Index
2/10
CAUTION! Company made loss in last quarter. Be careful.
Technical Breakdown
Moving Averages
3/10
BEARISH TREND! 50-day average (57.1) is below 200-day average (58.1) - negative signal.
Price Position
8/10
STRONG POSITION! Current price (60.2) is above both moving averages.
Trend Pattern
10/20
Current trend: CONSOLIDATION
52W Performance
2/10
WEAK YEAR! Stock declined 13.9% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 17 up days, 13 down days. Avg volume on up days: 63,338 vs down days: 21,677. Ratio: 2.92x
RSI
3/5
NEUTRAL! RSI at 53.8 - balanced momentum.
52W Range
3/5
MID RANGE! Trading at 56.9% of 52W range - neutral zone.
Momentum
5/5
STRONG MOMENTUM! Price has grown across all timeframes - up 7.5% (1 week), 8.2% (1 month), 12.1% (3 months). Momentum is accelerating.
Beta
4/5
BELOW MARKET! Beta of 0.90 - slightly less volatile than market.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KREBSBIO | ₹60.20 | – | -55.9% | -23.1% | – | -13.9% | 51 | CONSOLIDATION | -52.8% | +8.7% | +27.3% | +2.9% |
| PAR | ₹109.50 | 10.3 | 13.3% | 11.0% | 1.0% | +8.9% | 52 | BREAKDOWN | +42.7% | +423.3% | +20.3% | +59.6% |
| BALAXI | ₹22.10 | 49.1 | 0.9% | -7.1% | -68.6% | -46.1% | 48 | APPROACHING SUPPORT | +333.3% | +116.7% | +14.1% | +14.1% |
| ALPA | ₹53.50 | 31.8 | 3.8% | 4.3% | 6.1% | -34.9% | 47 | BREAKDOWN | -91.5% | -28.6% | +25.1% | -23.9% |
| BALPHARMA | ₹95.80 | 21.1 | 2.2% | 0.1% | 34.7% | +21.4% | 71 | CONSOLIDATION | +450.0% | -69.4% | +34.4% | +5.4% |
| VAISHALI | ₹7.80 | – | 4.1% | 18.0% | -15.2% | -22.7% | 51 | BREAKDOWN | – | +278.0% | – | -15.0% |
| NATCAPSUQ | ₹160.40 | – | -8.1% | 3.6% | – | -27.7% | 37 | BREAKDOWN | +1.8% | +14.0% | +7.7% | -16.8% |
| MEDICO | ₹22.00 | 13.2 | 5.8% | 13.8% | 21.9% | -54.4% | 58 | BOUNCE FROM SUPPORT | +38.9% | -57.6% | +81.2% | +22.2% |
Data from TradeAlone · Updated daily
No news tagged for KREBSBIO yet.
